𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The basis for individual bioequivalence

✍ Scribed by R. L. Williams; R. N. Patnaik; M-L. Chen; FDA Population and Individual Bioequivalence Working Group

Book ID
105731516
Publisher
Springer-Verlag
Year
2000
Tongue
English
Weight
524 KB
Volume
25
Category
Article
ISSN
0378-7966

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

TOLERANCE INTERVALS FOR ASSESSING INDIVI
TOLERANCE INTERVALS FOR ASSESSING INDIVIDUAL BIOEQUIVALENCE
✍ EILEEN B. BROWN; HARI K. IYER; C. MING WANG πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 276 KB

Evaluation of equivalence of two formulations of a drug typically entails the comparison of average bioavailabilities. Recently, however, authors have become aware that this may be insufficient to assess individual bioequivalence, that is, interchangeability of formulations on an individual basis. T

The bootstrap procedure in individual bi
The bootstrap procedure in individual bioequivalence
✍ Jun Shao; Shein-Chung Chow; Bill Wang πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 101 KB

A bootstrap-type hypothesis test procedure for assessing individual (or population) bioequivalence between two drug formulations is suggested in a draft guidance from the United States Food and Drug Administration (FDA). The purpose of this article is to study the unknown properties of this test pro

Some statistical considerations on the F
Some statistical considerations on the FDA draft guidance for individual bioequivalence
✍ Francis C. Hsuan πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 56 KB πŸ‘ 2 views

In December of 1997, the FDA proposed a draft guidance for future in vivo bioequivalence studies. The guidance suggested speciΓΏc criteria for new drug sponsors to show individual bioequivalence (IBE). The criteria use a mixed-scaling aggregate strategy. It has been generally accepted that, under som